Neonc Technologies (NTHI) Stock Price, News & Analysis

Company Overview

Neonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.

Key Stats

• Today's Range: $6.61 to $7.00
• 50-Day Range: N/A
• 52-Week Range: $6.10 to $25.00
• Volume: 20,451 shs
• Average Volume: 58,353 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NTHI Stock Analysis - Frequently Asked Questions

How have NTHI shares performed this year?

Neonc Technologies' stock was trading at $12.00 on January 1st, 2025. Since then, NTHI shares have decreased by 42.1% and is now trading at $6.95.
View the best growth stocks for 2025 here.

When did Neonc Technologies IPO?

Neonc Technologies (NTHI) raised $52 million in an initial public offering on Wednesday, March 26th 2025. The company issued 2,100,000 shares at a price of $25.00 per share. RBW Capital Partners (Division of Dawson James) acted as the underwriter for the IPO.

How do I buy shares of Neonc Technologies?

Shares of NTHI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Manufacturing
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:NTHI
• Previous Symbol: NASDAQ:NTHI
• CIK: 1979414
• Web: www.neonctech.com
• Phone: 310-663-7831
• Fax: N/A
• Employees: 8
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $83,000.00
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: N/A
• Beta: N/A